Nanobiotix (NBTX) Stock Insights
$1.56B
Market Cap
-27.47
P/E
75.48
Forward P/E
33
Score
NBTX price $33.52 -0.46 -1.35%
Stocklytics score rationale: value 56, quality 22, growth 20.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5421613 | 3722000 | 3479000 | 2541000 | 2325000 | 2647000 | 4776000 | 36208000 | -7190000 | 29643000 |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and…
Insights · Dividends · Forecast · Financials · Learn
$1.56B
Market Cap
-27.47
P/E
75.48
Forward P/E
33
Score